Therapeutic effects of direct renin inhibitor aliskiren added to AT1 receptor blocker in hypertensive patients with chronic kidney disease.

Trial Profile

Therapeutic effects of direct renin inhibitor aliskiren added to AT1 receptor blocker in hypertensive patients with chronic kidney disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 May 2016

At a glance

  • Drugs Aliskiren (Primary) ; Benazepril (Primary)
  • Indications Hypertension
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 19 Sep 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
    • 04 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
    • 29 Apr 2012 Interim results presented at the 22nd European Meeting on Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top